Eli Lilly & Co.’s blockbuster obesity shot Zepbound helped people with type 1 diabetes lose more than a fifth of their body ...

The injectable weight-loss drug Zepbound appears to work better in women than in men, according to a new analysis.

Lilly clearly has an abundance of growth drivers -- and the list includes more than Mounjaro, Zepbound, and the six drugs ...

The weight management drug Zepbound will now be sold in lower-cost vials in addition to preloaded injector pens, according to ...

These drugs work to treat diabetes and weight loss by suppressing the appetite and lowering blood sugar and A1C—which may end ...

Sept. 16, 2024 – Tiny bottles of the weight loss drug Zepbound have started arriving in mailboxes across the country. People who order the medicine directly from drugmaker Eli Lilly can pay much ...

The injectable weight-loss drug Zepbound appears to work better in women than in men, according to a new analysis of the ...

Although women lost more weight, all participants saw significant decreases in total body weight on all doses of the medication.

Eli Lilly's weight loss treatment Zepbound might be a blockbuster in the making, but it wasn't without its challenges. See ...

Forget Mounjaro: 1 Reason Investors Should Love Eli Lilly Stock Even More (Hint: I'm Not Talking About Zepbound) ...

Results from 4 studies revealed that women lost more weight on average than men when taking tirzepatide — but they also ...

Eli Lilly will now sell cheaper vials of Zepbound, presenting a direct challenge to telehealth companies that offer compounded versions of the medication. By Dani Blum With high demand for drugs ...